Aeglea BioTherapeutics Inc logo

AGLE

Aeglea BioTherapeutics Inc

$0.72

Earnings Summary

Revenue
$0.63Mn
Net Profits
$-22.32Mn
Net Profit Margins
-3571.68%

Highlights

Revenue:

Aeglea BioTherapeutics Inc’s revenue fell -95.44% since last year same period to $0.63Mn in the Q2 2022. On a quarterly growth basis, Aeglea BioTherapeutics Inc has generated -54.11% fall in its revenue since last 3-months.

Net Profits:

Aeglea BioTherapeutics Inc’s net profit fell -226.84% since last year same period to $-22.32Mn in the Q2 2022. On a quarterly growth basis, Aeglea BioTherapeutics Inc has generated 8.65% jump in its net profits since last 3-months.

Net Profit Margins:

Aeglea BioTherapeutics Inc’s net profit margin fell -7062.19% since last year same period to -3571.68% in the Q2 2022. On a quarterly growth basis, Aeglea BioTherapeutics Inc has generated -99.08% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Aeglea BioTherapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.31
EPS Estimate Current Year
-0.31

Highlights

EPS Estimate Current Quarter:

Aeglea BioTherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a 8.82% jump from last quarter’s estimates.

EPS Estimate Current Year:

Aeglea BioTherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.31.

Key Ratios

Key ratios of the Aeglea BioTherapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.43
Return on Equity (ROE)
-0.86
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aeglea BioTherapeutics Inc’s return on assets (ROA) stands at -0.43.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aeglea BioTherapeutics Inc’s return on equity (ROE) stands at -0.86.

Dividend Per Share (DPS):

Aeglea BioTherapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.34
-0.37
-8.82%

Company Information

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.

Organisation
Aeglea BioTherapeutics Inc
Headquarters
805 Las Cimas Parkway, Austin, TX, United States, 78746
Employees
90
Industry
Health Technology